RESEARCH

The Science

*Annotated Bibliography 12-6-2021

*Payaningal R Somanath and/or Brian S. Cummings, co-Founders of MetasTx, LLC are authors

2005

Chen, J., Somanath, P.R, Razorenova, O., Chen, WS, Hay, N, Bornstein,p., Byzova, T.V. Nature Medicine 2005.
https://pubmed.ncbi.nlm.nih.gov/16227992/
Akt1 regulates pathological angiogenesis, vascular maturation, and permeability in vivo.

2007

Payaningal R. Somanath, Eugene S. Kandel, Nissim Hay, and Tatiana V. Byzova. J Biol Chem. 2007
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731941/
Akt1 is essential for the inside-out activation of integrins in endothelial cells and fibroblasts, which in turn, mediates matrix assembly.

2009*

Payaningal R Somanath, Tatiana V Byzova. J Cell Physiol. 2009.
https://pubmed.ncbi.nlm.nih.gov/18853424/
importance of Rac1-Pak signaling in growth factor stimulated cytoskeletal assembly, lamellipodia formation and cell migration in endothelial cells and fibroblasts downstream of Akt1 activation

2009*

P R Somanath, J Vijai, J V Kichina, T Byzova, E S Kandel. Oncogene. 2009.
https://pubmed.ncbi.nlm.nih.gov/19421139/
PAK1 was implicated in the process by integrating ERK and Akt1 pathways In an in vitro model of oncogenic transformation.

2010*

Julia V Kichina, Anna Goc,Belal Al-Husein, Payaningal R Somanath, and Eugene S Kandel. Expert Opin Ther Targets. 2010.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137287/
Identifies PAK-1 as a Therapeutic Target

2011*

Goc A, Al-Hussein, B, Kochuparambil, S.T, Liu, J, Heston, WD, Somanath, P.R. 2011. PI3 Kinase integrates Akt and MAP Kinase signaling pathways in the regulation of prostate cancer. INT. J ONCOL. 38(1): 267-277
https://pubmed.ncbi.nlm.nih.gov/21109949/
Identifies the mechanism how PI3 kinase integrates the Akt and MAP Kinase pathways in PCa cells

2011*

Kochuparambil, S.T, Al-Husein B, Goc A, Soliman, S, Somanath, P.R. 2011. Anti-cancer Efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced expression of PSA. J PHARM. EXP. THER. 336(2): 496-505
https://pubmed.ncbi.nlm.nih.gov/21059805/
Identifies the therapeutic benefits of statins to suppress PCa growth

2012*

Anna Goc, Maha Abdalla, Ahmad Al-Azayzih, Payaningal R Somanath. PLoS One. 2012.
https://pubmed.ncbi.nlm.nih.gov/22808202/
Although PAK1 expression was reported to be absent in normal prostatic epithelial cells by others, this study reveals the existence of upstream regulator of PAK1 activation, the 14-3-3ζ -Rac1 pathway, in turn, promoting prostate cancer cell-matrix interactions, motility and transendothelial migration (invasion)

2012*

Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammed S, Somanath, P.R. 2012. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis, BMC CANCER. Sep 14;12(1):409
https://pubmed.ncbi.nlm.nih.gov/22974127/
Study shows how statins induce apoptosis in PCa cells

2012*

Al-Azayzih A, Gao F, Goc A, Somanath P.R. 2012. TGFβ1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/ SAPK-mediated activation of caspases, BIOCHEM. BIOPHYS. RES. COMMUN. 427: 165–170
https://pubmed.ncbi.nlm.nih.gov/22989755/
The study described the effect of TGF on PCa cells in vitro

2012*

Al-Husein B, Abdalla M, Trepte M, DeRemer D, Somanath, P.R. 2012. Anti-angiogenic therapy for cancer: An update, PHARMACOTHERAPY. Dec;32(12):1095-111
https://pubmed.ncbi.nlm.nih.gov/23208836/
Review article describing potential anti-angiogenic therapies for cancer

2013*

Anna Goc, Ahmad Al-Azayzih, Maha Abdalla, Belal Al-Husein, Sravankumar Kavuri, Jeffrey Lee, Kelvin Moses, Payaningal R Somanath. J. Biol. Chem. 2013
https://pubmed.ncbi.nlm.nih.gov/23258534/
Identifies that, although PAK1 is absent in normal human epithelial cells, it is expressed in PCa cells and human PCa patient samples correlating to its metastatic potential

2013*

Al-Husein B, Goc A, Somanath PR, 2013. Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. J CELL PHYSIOL. 228(11):2139-48.
https://pubmed.ncbi.nlm.nih.gov/23559257/
Study showed how statins could block vascular penetration of PCa cells

2013*

J N Mock, L J Costyn, S L Wilding, R D Arnold, B S Cummings. 2013. Integr Biol (Camb).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164335/
Demonstrated the therapeutic activity of secretory phospholipase A2 (SPRL) in prostate cancer

2014*

Goc A, Al-Husein B, Katsanevas, K, Steinbach A, Lou U, Sabbineni H, DeRemer, D, Somanath P.R. (2014), Src-mediated tyrosine phosphorylation of GSK-3β is essential for prostate cancer micrometastasis ONCOTARGET. 15;5(3):775-87.
https://pubmed.ncbi.nlm.nih.gov/24519956/
The study described how targeting Src by Dasatinib and GSK3 by SB415286 could treat PCa

2014*

Alhusban A, Al-Azayzih A, Goc A, Fagan S.C., Somanath P.R., 2014. Clinically relevant doses of candesartan inhibit prostate cancer growth in vivo. J PHARM EXP THER., Sep; 350(3):635-45.
https://pubmed.ncbi.nlm.nih.gov/24990940/
The study showed how angiotensin receptor blocker, candesartan can suppress tumor growth via vascular normalization.

2015*

Sabbineni H, Alwhaibi A, Goc A, Gao F, Pruitt A, Somanath PR. Genetic deletion and pharmacological inhibition of Akt1 isoform attenuate bladder cancer cell proliferation, motility, and invasion. EUR J PHARMACOL. 2015 Oct 5; 764:208-14.
https://pubmed.ncbi.nlm.nih.gov/26148825/
The study showed the importance of Akt in prostate and bladder cancer cell proliferation and survival

2015*

Ahmad Al-Azayzih, Fei Gao, Payaningal R Somanath. Biochim Biophys Acta. 2015
https://pubmed.ncbi.nlm.nih.gov/25746720/
Suggests role of PAK-1 (target of IPA-3) in prostate cancer cells in vitro. IPA3 was proven to inhibit aggressiveness of PCa cells in vitro, albeit with higher doses, probably due to anticipated loss of activity of unstable IPA3 once administered I.v.

2015*

Gao F, Al-Azayzih A, Somanath PR. Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis. ONCOTARGET. 2015 Mar20;6(8):5947-62.
https://pubmed.ncbi.nlm.nih.gov/25714023/
The study showed distinct roles and potehtial therapeutic benefits of targeting two different GSK3 isoforms in PCa growth and metastasis.

2016*

Ahmad Al-Azayzih, Wided N Missaoui, Brian S Cummings, Payaningal R Somanath. 2016. Nanomedicine.
https://pubmed.ncbi.nlm.nih.gov/26949163/
Demonstrated the efficacy of IPA-3 loaded liposomes against prostate cancer growth in vivo using a xenograft mouse model

2016*

Gao F, Artham S, Sabbineni H, Al-Azayzih A, Peng XD, Hay N, Adams RH, Byzova TV and Somanath P.R. 2016, Endothelial-specific Akt1 loss blunts Angiopoietin-1 and VEGFInduced endothelial barrier protection through tight-junction turnover. CELL MOL LIFE SCI. Oct;73(20):3917-33.
https://pubmed.ncbi.nlm.nih.gov/27113546/
Study showed the mechanisms how targeting Akt1 could promote vascular permeability

2017*

Wang R, Bridges A, Islam B, Sharman S, Hu M, Somanath PR, Venable L, Singh N, Kim S, Sridhar S, Hofmann F and Browning DD. 2017, Cyclic-GMP signaling increases antioxidant gene expression by activating FoxO3a in the colon epithelium. AM J PATHOL. 187: 377-389.
https://pubmed.ncbi.nlm.nih.gov/27998725/
The study showed the role of FoxO3a, a substrate of Akt, in Colon cell neoplasia

2017*

Fei Gao, Abdulrahman Alwhaibi, Harika Sabbinen, Arti Verma, Wael Eldahshan, Payaningal R Somanath. Cancer Lett. 2017.
https://pubmed.ncbi.nlm.nih.gov/28602980/
Demonstrates a novel role of the Akt1-β-catenin-TGFβ1 pathway in advanced PCa.

2018*

Alwhaibi A, Gao F, Artham S, Hsia BM, Mondal A, Kolhe R, Somanath PR. Modulation in the microRNA repertoire is responsible for the stage-specific effects of Akt suppression on murine neuroendocrine prostate cancer. HELIYON. 2018 Sep 17;4(9): e00796.
https://pubmed.ncbi.nlm.nih.gov/30238065/
Study identified novel microRNA candidates regulated by Akt1 in the regulation of PCa metastasis

2018*

Gao F, Alwhaibi A, Artham S, Verma A, Somanath PR. Br J Cancer. 2018
https://pubmed.ncbi.nlm.nih.gov/29755115/
We show for the first time that endothelial-specific loss of Akt1 promotes cancer metastasis in vivo involving β-catenin pathway.

2019*

Sabbineni H, Verma A, Artham S, Anderson D, Amaka A, Liu FL, Narayanan SP, Somanath PR. Pharmacological inhibition of β-catenin prevents EndMT in vitro and vascular remodeling in vivo resulting from endothelial Akt1 suppression. BIOCHEM PHARMACOL. 2019 June; 164: 202-215.
https://pubmed.ncbi.nlm.nih.gov/30991049/
The study demonstrated that targting beta-catenin by ICG-001 suppresses endothelial-to-mesenchymal transition (EndMT, similar to the EMT in epithelial/cancer cells). EndMT has been reported to be improtant also in cancer metastasis by others.

2018*

2019*

Alwhaibi A, Kolhe R, Gao F, Kobran EK, Somanath PR. Genome atlas analysis-based profiling of Akt pathway genes in the early and advanced human prostate cancer. ONCOSCIENCE. 2019 Jul 2;6(5-6): 317-336.
https://pubmed.ncbi.nlm.nih.gov/31360736/
The study identified that Akt suppression in advanced cancers promote cancer metastasis based on human data from cBioportal database

2019*

Wided Najahi-Missaoui, Nhat D Quach, Amber Jenkins, Isha Dabke, Payaningal R Somanath, Brian S Cummings. Pharmacol Res Perspect. 2019
https://pubmed.ncbi.nlm.nih.gov/31516713/
Demonstrated that both pharmacological and molecular inhibition of PAK-1 decreased growth in prostate, breast, and melanoma cancer cell lines.

2019*

Alwhaibi A, Verma A, Adil MS, Somanath PR. Pharmacol Res. 2019
https://pubmed.ncbi.nlm.nih.gov/31078742/
The unconventional role of Akt1 in advanced cancers and diabetes-promoted carcinogenesis.

2020*

Arti Verma, Wided Najahi-Missaoui, Brian S Cummings, Payaningal R Somanath. Oncol Lett. 2020.
https://pubmed.ncbi.nlm.nih.gov/32934746/
Twice-a-week administration of either SSL-IPA3 or SPRL-IPA3 for 3 weeks effectively suppressed the growth of PC-3 cell tumor xenografts implanted in athymic nude mice. Both drug formulations also inhibited metastasis of intravenously administered murine RM1 PCa cells to the lungs of C57BL/6 mice

2020*

Arti Verma, Sandeep Artham, Abdulrahman Alwhaibi, Mir S Adil,Brian S Cummings, Payaningal R Somanath. 2020. Biochem Pharmacol.
https://pubmed.ncbi.nlm.nih.gov/32240651/
Demonstrated the ability of IPA-3 to inhibit bone-loss induced by prostate cancer cells in a clinically relevant mouse model

2020*

Wided Najahi-Missaoui, Nhat D Quach, Payaningal R Somanath, Brian S Cummings. 2020. Int J Mol Sci.
https://pubmed.ncbi.nlm.nih.gov/33321758/
Demonstrated the ability of IPA-3 liposomes to induce cell death in metastatic triple-negative breast cancer

2020*

Wided Najahi-Missaoui, Robert D. Arnold and Brian S. Cummings, Safe Nanoparticles: Are we there yet? Int J Mol Sci, 22(1):385, 2020.
https://pubmed.ncbi.nlm.nih.gov/33396561/
This review article describes the history and use of nanoparticles. It emphasizes the different types of nanoparticles and their emerging use to delivery therapeutic drugs for treatment of cancer

2021*

L.M. Ingram, M.C. Finnerty, M. Mansoura, C-W. Chou and B.S. Cummings, Identification of lipidomic profiles associated with drug-resistant prostate cancer cells. Lipids Health Dis, 20(1):15, 2021.
https://pubmed.ncbi.nlm.nih.gov/33596934/
This study identifies how the lipid profiles of prostate cancer changes as they progress from benign to aggressive drug resistance prostate cancer. It also identified a protein called lipin that may be a novel therapeutic target for treatment of drug-resistant prostate cancer

2021*

Kaur S.P., Verma A, Lee H.K., Barnett L.M., Somanath, P.R. and B.S. Cummings, Sci Reports, 29:11: 9262, 2021.
https://pubmed.ncbi.nlm.nih.gov/33927256/
This study suggest that a protein called glypican-1 is a tumor suppressor that inhibits the growth of prostate cancer cells by inhibiting the ability of fibroblast to become activated and change the tumor microenvironment

MetasTx, LLC
100 S Jackson Ave.
Pittsburgh, PA 15202

MetasTx, LLC
100 S Jackson Ave.
Pittsburgh, PA 15202